Your browser is no longer supported. Please, upgrade your browser.
Settings
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E61.21 EPS (ttm)1.97 Insider Own0.20% Shs Outstand225.80M Perf Week10.93%
Market Cap27.20B Forward P/E14.29 EPS next Y8.43 Insider Trans-10.93% Shs Float220.51M Perf Month0.10%
Income443.30M PEG3.25 EPS next Q1.50 Inst Own97.20% Short Float2.78% Perf Quarter9.18%
Sales3.55B P/S7.66 EPS this Y11.90% Inst Trans-0.69% Short Ratio2.88 Perf Half Y-10.52%
Book/sh39.77 P/B3.03 EPS next Y23.20% ROA3.30% Target Price157.10 Perf Year-7.61%
Cash/sh6.53 P/C18.45 EPS next 5Y18.84% ROE5.00% 52W Range96.18 - 149.34 Perf YTD0.74%
Dividend- P/FCF35.87 EPS past 5Y8.90% ROI4.30% 52W High-19.33% Beta1.12
Dividend %- Quick Ratio2.60 Sales past 5Y25.60% Gross Margin87.20% 52W Low25.25% ATR4.71
Employees2525 Current Ratio3.10 Sales Q/Q9.60% Oper. Margin17.70% RSI (14)52.85 Volatility5.10% 4.03%
OptionableYes Debt/Eq0.36 EPS Q/Q-66.50% Profit Margin12.50% Rel Volume1.77 Prev Close122.71
ShortableYes LT Debt/Eq0.34 EarningsFeb 08 BMO Payout0.00% Avg Volume2.13M Price120.47
Recom1.80 SMA200.89% SMA501.55% SMA200-3.22% Volume3,764,674 Change-1.83%
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-03-16Initiated Deutsche Bank Buy $164
Feb-14-18 05:15PM  Top Research Reports for ExxonMobil, Caterpillar & Union Pacific Zacks +8.10%
Feb-12-18 01:20PM  Alexion loses two executives amid Boston relocation American City Business Journals +6.29%
Feb-10-18 02:33PM  3 ETFs to Watch on Biotech Earnings Zacks
Feb-08-18 04:17PM  Alexion Tops Quarterly Views But Guidance Lags; Alnylam Dips On Losses Investor's Business Daily -7.41%
02:02PM  Does Alexion Pharmaceuticals Incs (NASDAQ:ALXN) PE Ratio Signal A Selling Opportunity? Simply Wall St.
10:22AM  Alexion's (ALXN) Earnings and Sales Beat Estimates in Q4 Zacks
08:30AM  Alexion Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
08:17AM  Alexion (ALXN) Tops Q4 Earnings and Revenues Beat Estimates Zacks
06:53AM  Alexion tops Street 4Q forecasts Associated Press
06:30AM  Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018 Business Wire
Feb-07-18 10:12AM  REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings? Zacks
08:38AM  Why Earnings Season Could Be Great for Alexion Pharmaceuticals (ALXN) Zacks
Feb-06-18 07:30PM  Data Presented at WORLDSymposium 2018 Show Survival to 3 Years of Age and Improvements in Liver Function in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma® (sebelipase alfa) Business Wire
01:09PM  5 Biotech Stocks Set to Trump Estimates This Earnings Season Zacks
Feb-05-18 04:05PM  Alexion Appoints Judith A. Reinsdorf, J.D., to its Board of Directors Business Wire
10:03AM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
Feb-01-18 03:29PM  Despite Doubters, Moderna Raises $500 Million, Is Now Worth $7 Billion Forbes
Jan-31-18 10:00AM  Alexion to Present at the Leerink Partners 7th Annual Global Healthcare Conference Business Wire
Jan-23-18 05:30PM  Alexion adds ex-Millennium CEO Dunsire to board amid activist pressure American City Business Journals
07:56AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck Zacks
Jan-22-18 04:05PM  Alexion Appoints Deborah Dunsire, M.D. to Its Board of Directors Business Wire
12:20PM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? InvestorPlace
08:47AM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? Zacks
Jan-18-18 02:39PM  The Key To Alexion's Long-Term Upside Potential, According To Credit Suisse Benzinga
10:00AM  Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018 Business Wire
Jan-16-18 08:08AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Jan-12-18 09:16AM  The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex Zacks
Jan-10-18 03:05PM  How Mylans North America Segment Performed in 3Q17 Market Realist
02:35PM  A Look at Ionis Pharmaceuticals January 2018 Valuation Market Realist
Jan-09-18 10:23AM  Hows Incytes Valuation in January 2018? Market Realist
08:01AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Jan-08-18 01:19PM  How To Trade The JPMorgan Healthcare Conference Benzinga
Jan-04-18 10:40AM  Sorry Alexion! Biotech Rally Will Leave You Behind Barrons.com
08:00AM  5 Stock Winners From Wall Street's Top Analysts Investopedia
Jan-03-18 01:53PM  Alexion, PayPal, Comcast & Visa CNBC Videos
07:11AM  Will These 2 Large-Cap Biotechs Be on Investor Radar in '18? Zacks
Jan-02-18 07:27PM  [$$] Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat The Wall Street Journal
04:23PM  Alexion, Elliott to jointly look for new director Reuters
04:17PM  Alexion, Elliott to collaborate on new Alexion board memb... CNBC Videos
04:11PM  Why These 2 Biotechs Could Outperform Amid 'Hyper-Competition' Investor's Business Daily
04:05PM  Alexion and Elliott Agree to Collaborate on Identifying a New Board Member Business Wire
02:45PM  Piper Jaffray analyst: What to expect from biotech in 201... CNBC Videos
01:10PM  Analyst names Vertex and Alexion 'top picks for 2018' American City Business Journals
10:00AM  Alexion to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-29-17 09:40PM  [$$] Dow Industrials End Solid 2017 on a Sour Note Barrons.com
Dec-28-17 07:00AM  Wired News - Alexion Announced Marketing Authorization of Soliris® in Japan for Treatment of Patients with Generalized Myasthenia Gravis ACCESSWIRE
Dec-27-17 08:11AM  Alexion's (ALXN) Soliris Label Expansion Approved in Japan Zacks
Dec-26-17 06:30AM  Soliris® (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG) Business Wire
Dec-20-17 05:05PM  Oppenheimer Stays Bullish On Alexion Pharma Benzinga
10:00AM  Alexion to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference Business Wire
Dec-19-17 03:48PM  7 Hot Investing Bets to Make in Biotech TheStreet.com
02:14PM  7 Best Bets in Biotech: From Alexion to Regeneron TheStreet.com
Dec-18-17 04:26PM  Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018 Investor's Business Daily
Dec-12-17 12:42PM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : December 12, 2017 Capital Cube
Dec-11-17 10:00AM  Results of Phase 1b/2 Dose Regimen Optimization Studies for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented at American Society of Hematology (ASH) Meeting Business Wire
09:02AM  Analyst Recommendations for Alexion in December 2017 Market Realist
08:41AM  Alexion (ALXN) in Focus: Stock Moves 7.2% Higher Zacks
08:20AM  4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018 Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Gilead Sciences and Alexion Pharmaceuticals ACCESSWIRE
07:32AM  Alexion Pharmaceuticals Strensiq and Kanuma after 3Q17 Market Realist
Dec-10-17 08:43PM  Analysts expect these large-cap U.S. stocks to rise at least 25% in 2018 MarketWatch
Dec-08-17 04:46PM  Elliott Management seeks changes at Alexion - NYT Reuters +7.19%
04:35PM  Elliott Management seeks changes at Alexion - NYT Reuters
04:35PM  A Look at Alexion Pharmaceuticals Soliris after 3Q17 Market Realist
04:25PM  The Hot Stock: Alexion Pharmaceuticals Jumps 7.2% Barrons.com
04:09PM  Why This Biotech Could See 30% Upside In The Second Quarter Investor's Business Daily
03:02PM  How Is Alexion Pharmaceuticals Positioned after 3Q17? Market Realist
01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
11:51AM  Elliott Management Flexes Muscle at Alexion Barrons.com
11:30AM  Boston-bound Alexion sees shares jump amid reported activist pressure American City Business Journals
09:56AM  Alexion Spikes Amid Report Activist Elliott Management Is Pushing for Change TheStreet.com
09:40AM  Will Alexion Pharmaceuticals Fight This Activist? 24/7 Wall St.
09:30AM  Stocks to Watch: Amazon, Caterpillar, Alexion, 3M, United Continental, American Outdoor The Wall Street Journal
08:42AM  Stocks making the biggest moves premarket: GM, NKE, ALXN, TRVG & more CNBC
06:37AM  Elliott Management seeks changes at Alexion - NYT (Dec. 7) Reuters
12:51AM  PRESS DIGEST-New York Times business news - Dec 8 Reuters
Dec-07-17 10:19PM  Barron's After Hours: Forescout Jumps, Alexion Gains, Smith & Wesson Parent Slumps Barrons.com
09:26AM  Sage Therapeutics Skyrockets on Data for Depression Drug -- Biotech Movers TheStreet.com
06:30AM  Alexion and Halozyme Enter License Agreement for ENHANZE Technology Business Wire
Dec-05-17 01:22PM  Why Alexion Pharmacteuicals Sank 8.9% in November Motley Fool
Dec-04-17 04:54PM  Why Ra Pharmaceuticals, Inc. Got Hammered Today Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Dec-01-17 08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-30-17 10:17AM  Oppenheimer's Top Stock Picks For December Benzinga
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-28-17 10:49AM  Why Omeros Corporation Is the Best Buy in Biotech Right Now Motley Fool
03:53AM  Alexion (ALXN) Down 14.6% Since Earnings Report: Can It Rebound? Zacks
Nov-27-17 11:56AM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 27, 2017 Capital Cube
10:00AM  Alexion to Present at the Citi 2017 Global Healthcare Conference Business Wire
08:20AM  Today's Research Reports on Trending Tickers: Acorda Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-23-17 08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
07:21AM  Has Alexion Pharmaceuticals Inc (ALXN) Improved Earnings Growth In Recent Times? Simply Wall St.
Nov-20-17 08:03AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-15-17 10:47AM  3 Big Stock Charts for Wednesday: Alexion Pharmaceuticals, Inc., Alliance Data Systems Corporation and Snap-on Incorporated InvestorPlace
08:02AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-14-17 08:04AM  See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc. Markit
Nov-13-17 03:05PM  Alexion Suffers Quantitative Downgrade, Bearish Charts TheStreet.com
11:37AM  ETFs with exposure to Alexion Pharmaceuticals, Inc. : November 13, 2017 Capital Cube
Nov-09-17 06:30AM  Alexion Employees Volunteer Together to Enhance Their Local Communities during Second Annual Global Day of Service Business Wire
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Goff BrianEVP & Chief Commercial OfficerFeb 08Sale116.311,651192,02828,962Feb 08 07:17 PM
Moriarty John BEVP & General CounselFeb 08Sale115.703,363389,09974,537Feb 08 07:16 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale116.314,787556,77644,412Feb 08 07:16 PM
Franchini Indrani LallEVP, Chief Compliance OfficerFeb 08Sale116.311,459169,69625,031Feb 08 07:16 PM
Clancy Paul JEVP, Chief Financial OfficerFeb 08Sale116.316,079707,04889,014Feb 08 07:17 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale116.311,774206,33449,838Feb 08 07:17 PM
HANTSON LUDWIGCEOFeb 08Sale116.3113,2451,540,526118,180Feb 08 07:16 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale117.2665576,80532,635Feb 07 06:36 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale117.262,119248,47420,210Feb 07 06:35 PM
Moriarty John BEVP & General CounselFeb 05Sale117.261,261147,86549,911Feb 07 06:35 PM
HANTSON LUDWIGCEOJan 02Sale121.632,553310,52136,172Jan 04 06:33 PM
Wagner Heidi LSVP, Global Government AffairsOct 02Sale140.0012016,80033,290Oct 04 05:25 PM
Veneman Ann MDirectorSep 05Sale145.81835121,7515,480Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsSep 05Sale146.003,763549,38122,329Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsAug 31Sale142.0061286,90426,092Sep 05 07:28 PM
O'Neill JulieEVP. Global OperationsAug 28Sale140.0011,1601,562,40026,704Aug 30 06:13 PM
Veneman Ann MDirectorJul 31Sale137.7470096,4186,315Aug 02 05:18 PM
COUGHLIN CHRISTOPHER JDirectorJun 15Buy117.102,000234,2006,333Jun 16 04:55 PM
BAKER BROS. ADVISORS LPDirectorJun 15Buy117.33656,38777,012,4917,645,906Jun 16 04:04 PM
PARVEN ALVIN SDirectorJun 15Sale116.7883597,5117,568Jun 16 04:54 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy116.321,348,955156,915,4447,317,906Jun 16 04:03 PM
BAKER BROS. ADVISORS LPDirectorJun 14Buy118.004,392518,2567,321,850Jun 16 04:04 PM
HANTSON LUDWIGCEOJun 14Buy116.7210,0001,167,20038,725Jun 19 05:21 PM
O'Neill JulieEVP. Global OperationsMar 02Sale133.8065187,10437,864Mar 06 06:03 PM
Moriarty John BEVP & General CounselMar 01Sale132.5028237,36544,672Mar 01 07:46 PM
MACKAY MARTINEVP & Global Head of R&DMar 01Sale132.5037049,02550,688Mar 01 07:45 PM
BELL LEONARDDirectorMar 01Sale132.501,240164,300390,670Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsMar 01Sale132.5015620,67029,010Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerMar 01Sale132.5040453,53039,161Mar 01 07:44 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 28Sale131.013,783495,61133,860Mar 06 06:03 PM
Carmichael ClareEVP, Chief HR OfficerFeb 28Sale131.71915120,51533,065Mar 01 07:44 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale131.7048063,21629,166Mar 01 07:44 PM
BELL LEONARDDirectorFeb 28Sale131.712,738360,622391,910Mar 01 07:44 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale131.7066487,44931,015Mar 01 07:46 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 28Sale131.7033043,46114,884Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 28Sale131.7062582,31338,258Mar 01 07:45 PM
Moriarty John BEVP & General CounselFeb 28Sale131.71910119,85644,954Mar 01 07:46 PM
Moriarty John BEVP & General CounselFeb 27Sale131.2061280,29445,864Mar 01 07:46 PM
Thiel CarstenEVP, Chief Commercial OfficerFeb 27Sale131.20719,31530,197Mar 01 07:45 PM
MACKAY MARTINEVP & Global Head of R&DFeb 27Sale131.20860112,83238,883Mar 01 07:45 PM
Miller EdwardSVP, Chief Compliance OfficerFeb 27Sale131.2026034,11215,214Mar 01 07:45 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale131.20910119,39231,679Mar 01 07:46 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale131.2035846,97029,646Mar 01 07:44 PM
Carmichael ClareEVP, Chief HR OfficerFeb 27Sale131.20860112,83233,980Mar 01 07:44 PM